Four steps, one causal chain: from clinical network formation to attributable outcomes and durable value capture.
Value-based care has solved the principle. Clinical interventions that improve outcomes should drive provider economics, and the industry has accepted that premise for years. The proof has remained elusive, because no infrastructure has produced verifiable outcomes attribution at the patient-encounter level.
EPO produces that attribution. We drive clinical pharmacy interventions from the pharmacy into the patient's medication cabinet through pharmacy-provider clinical integrations that respect each stakeholder's scope of practice. Pharmacists capture the medication cabinet reality. Providers direct therapy. Both optimize medication therapy together, before that therapy becomes a retrospective data point for review. Every pharmacy-patient interaction enters a cause-and-effect record that is active, accurate, and pertinent.
EPO is medication management infrastructure. We connect pharmacists and providers into clinical partnerships that produce better patient care, and we generate the outcomes attribution that proves it was delivered. Clinical work and economic value finally line up because the evidence layer between them now exists.
EPO builds clinically integrated networks (CINs) market by market. Each CIN brings together local providers, the pharmacies serving their patients, and EPO operating as the MSO. Governance is local. Contracting is local. The clinical relationships already exist in the market — EPO's role is to give them a coordinated operating structure.
This step matters because attribution is only as credible as the clinical relationship it sits on top of. A CIN creates the contractual, data, and clinical foundation that everything downstream depends on.
Inside every CIN, EPO deploys proprietary medication management protocols. These algorithms identify care gaps, surface medication-related problems, and drive clinical interventions tied to specific patient outcomes. Every clinical review is structured; every intervention is captured as data.
The protocols are condition-agnostic in design and tuned market-by-market to the patient populations the CIN serves. Renal, cardiometabolic, behavioral health, oncology — the underlying method is the same: structured clinical review, documented intervention, measurable outcome.
EPO's technology platform captures the causal chain from intervention to outcome in real time. Not a retrospective audit. Not a claims-based proxy. A prospective, structured record that links a specific clinical action to a specific outcome — the kind of evidence base payers and risk-bearing entities can actually underwrite.
This is the step most healthcare organizations skip. Everyone believes their interventions work. Almost no one can prove which ones, for which patients, with what effect. EPO's infrastructure is designed specifically to produce that proof as a byproduct of normal clinical operations.
With attributable outcomes data in hand, the CIN is positioned to negotiate shared savings with payers, participate in outcomes-based arrangements with manufacturers, and enter federal value-based payment pathways. The economics shift from fee-for-service volume to total cost of care performance — and the evidence base makes those conversations credible.
Value capture is the last step, not the first. Trying to sell outcomes-based contracts without the underlying attribution infrastructure is why so many value-based pilots stall. The order of operations is the product.
EPO partners with providers, payers, and pharmacies to build clinical infrastructure that connects intervention to outcome.
Get in Touch